Hims & Hers Health Stock: Analysts Weigh Growth Catalysts Amid Recent Pullback

Hims & Hers Health (HIMS) has seen its stock surge 130% year-to-date, emerging as a standout in the digital health sector. Yet a 16% decline since late July has investors questioning the sustainability of its rally. Analysts remain divided, with some viewing the dip as a temporary pause and others pointing to long-term growth drivers in telehealth and weight-loss treatments.

Canaccord Genuity analyst Maria Ripps maintains a Buy rating and $68 price target, arguing that recent weakness stems from short-term concerns rather than structural issues. The shift of sexual health subscribers to daily plans may slow growth temporarily but creates a more loyal customer base and sets up favorable comparisons for 2026. Ripps also highlights regulatory tailwinds, including FDA guidance and a court decision favoring Willow Health in its GLP-1 drug dispute with Eli Lilly, as positive for Hims' expanding GLP-1 business.